Results 121 to 130 of about 23,074,058 (199)

Metabolic and Inflammatory Adverse Drug Reactions Associated with Amlodipine: A Descriptive and Disproportionality Analysis of EudraVigilance Reports. [PDF]

Pharmaceuticals (Basel)
Solomon CC, Butuca A, Frum A, Dobrea CM, Morgovan C, Palade NA, Pintea AL, Dădârlat DA, Ghibu S, Batar F, Tilinca MC, Gligor FG.   +11 more
europepmc   +1 more source

Post-marketing safety signal profile of mavacamten in the FDA adverse event reporting system (FAERS): a disproportionality analysis. [PDF]

Front Pharmacol
Wu J, Chen C, Zheng T.
europepmc   +1 more source

Safety assessment for ibuprofen using disproportionality analysis: a decade of data from the Romanian national pharmacovigilance system. [PDF]

Front Pharmacol
Buciuman CA, Butuca A, Frum A, Gligor FG, Ganea M, Vicaş LG, Marian E, Gligor O, Dobrea CM, Moisa CF, Pallag A, Jurca T, Morgovan C.   +12 more
europepmc   +1 more source

Disproportionality Analysis of Fluoroquinolone-Associated Peripheral Neuropathy in the FAERS Database (2007-2024). [PDF]

Clin Transl Sci
Shamim N, Doughty K, Chau HT, Brown J, Baldock R, Au NPB.   +5 more
europepmc   +1 more source

Digoxin Dosing Errors, Drug Interactions and Off-Label Risks: Insights from an EudraVigilance Disproportionality Analysis. [PDF]

J Clin Med
Fiat ES, Stoicescu L, Popa Ilie IR, Vonica RC, Butuca A, Dobrea CM, Frum A, Morgovan C, Batar F, Solomon CC, Gligor FG.   +10 more
europepmc   +1 more source